Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Company Overview
Innate Pharma SA (IPHA) is a clinical-stage biotechnology company that has made significant strides in the field of immuno-oncology by developing innovative therapeutic antibodies. By harnessing the innate immune system, the company addresses unmet medical needs in cancer treatment. Its work in mobilizing natural killer (NK) cells to recognize and eradicate cancer cells places it at a unique intersection of cutting‐edge science and clinical application.
Clinical Pipeline and Technological Innovations
The company has built a diversified pipeline comprising first-in-class clinical stage antibodies and preclinical candidates. Its proprietary platforms, such as the antibody-based NK cell engager therapeutics framework, exemplify its commitment to advancing immunotherapies. This technological edge has allowed Innate Pharma SA to explore a broad range of cancer indications and develop treatments that aim to provide improved outcomes and more targeted therapeutic effects.
Strategic Collaborations and Revenue Model
Revenue for Innate Pharma SA is generated primarily through research agreements, licensing deals, and strategic collaborations with established biopharma companies. These partnerships not only provide financial support but also validate the scientific merit of its approach. Collaborations with industry giants have enabled the company to accelerate clinical development and expand its research capabilities, underlining its credibility within the scientific community.
Innovative Approach and Core Expertise
At the core of Innate Pharma SA’s strategy is an innovative approach that leverages the innate immune system’s natural ability to combat cancer. The company’s deep expertise in natural killer cell biology distinguishes its methods from conventional immunotherapies that primarily target adaptive immune responses. This focused approach has paved the way for the discovery and development of novel checkpoint inhibitors and other therapeutic antibodies which are designed to reinvigorate the immune response against malignancies.
Market Position and Industry Significance
Innate Pharma SA is positioned as a pioneering entity within the immunotherapy sector. Its innovative research and comprehensive pipeline contribute to its reputation as an organization with substantial scientific industrial relevance. By addressing complex cancer biology through innovative solutions, the company plays a critical role in the broader narrative of modern oncology and immunotherapy. The content herein offers an in-depth perspective on how its clinical-stage initiatives and collaborative model set it apart in a competitive landscape.
Research, Development, and Operational Excellence
The company emphasizes a rigorous research and development ethos, meticulously navigating the challenges and complexities of immuno-oncology. Its operational strategy is built on scientific excellence and the clear intent to explore transformative cancer therapies. This approach not only reinforces its research credentials but also ensures that every innovation is subjected to strict scientific scrutiny, thereby upholding high standards of quality and efficacy.
Summary
In summary, Innate Pharma SA is a clinical-stage biotechnology company committed to transforming cancer treatment through its advanced immunotherapies. With a diversified pipeline, robust technological innovations, and strategic partnerships, the company represents a notable presence in the landscape of immuno-oncology. Its work in harnessing the innate immune system through novel therapeutic antibodies continues to influence the evolution of cancer treatment modalities in a meaningful way.
Innate Pharma (Nasdaq: IPHA) has scheduled a conference call and webcast to discuss its full year 2024 financial results on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT.
Key executives participating in the call will include Jonathan Dickinson (CEO), Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Frédéric Lombard (SVP, Chief Financial Officer).
The webcast will be accessible through the company's website, with a replay available for 90 days following the event.
Innate Pharma (Nasdaq: IPHA) has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference in Miami, Florida. The event will take place at the W Hotel South Beach from March 10-12, 2025.
The company's executive team will engage in two key activities during the conference: conducting one-on-one meetings with attendees and participating in a fireside chat scheduled for Tuesday, March 11, 2025, from 3:00 to 3:30 pm ET. Both a live webcast and replay of the presentation will be accessible through the Events page in the Investors section of Innate Pharma's website.
Innate Pharma announced that the U.S. FDA has granted Breakthrough Therapy Designation (BTD) to lacutamab for treating adult patients with relapsed or refractory Sézary Syndrome after at least 2 prior systemic therapies including mogamulizumab. The designation is based on Phase 1 and Phase 2 TELLOMAK study results, which showed encouraging efficacy and favorable safety profile in heavily pretreated patients.
The BTD aims to accelerate development and regulatory review of drugs treating serious conditions. This adds to lacutamab's previous Fast Track designation (2019) and PRIME designation by European Medicines Agency (2020). The company is currently aligning with regulatory agencies regarding a confirmatory Phase 3 trial in Cutaneous T Cell Lymphoma and seeking a partnership.
Innate Pharma has announced the dosing of the first patient in its Phase 1 study of IPH4502, a novel antibody-drug conjugate (ADC) targeting Nectin-4, in patients with advanced solid tumors. The study (NCT06781983) will evaluate the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent.
The trial consists of two parts: Part 1 Dose Escalation and Part 2 Dose Optimization, planning to enroll approximately 105 patients. The study targets tumors known to express Nectin-4, including urothelial carcinoma, breast cancer, non-small cell lung cancer, and gastro-intestinal cancer.
IPH4502 is designed with a differentiated topoisomerase I inhibitor payload, potentially offering benefits for patients with tumors resistant to MMAE-ADC. The drug targets tumors with both high and low Nectin-4 expression levels, supporting its development beyond urothelial carcinoma.
Innate Pharma (Nasdaq: IPHA) has announced an upcoming investor and analyst event focused on its Antibody-Drug Conjugate (ADC) strategy, specifically highlighting IPH4502, their lead Nectin-4 antibody-drug candidate program. The hybrid event will take place in New York on February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.
The company will present the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment. The event will be accessible both in-person and via webcast, with a replay available on Innate Pharma's website.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has released its share and voting rights data as of December 31, 2024. The company reported 83,830,336 ordinary shares, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 84,585,576, which includes voting rights attached to AGAP 2016 (130 voting rights for AGAP 2016-1 and 111 for AGAP 2016-2). The total number of exercisable voting rights is 84,567,001, calculated excluding treasury shares. No voting rights are attached to AGAP 2017.
Innate Pharma (Nasdaq: IPHA) announced a new growth strategy based on three key pillars: driving innovation with their proprietary ANKET® NK-cell engager Platform, accelerating development of Antibody-Drug Conjugates (ADCs), and advancing late-stage assets through partnerships.
The company is developing IPH6501, an ANKET® therapy currently in Phase 1/2 study for CD20-expressing non-Hodgkin's Lymphoma, and IPH4502, a topoisomerase I inhibitor ADC targeting Nectin-4 in Phase 1 trials for advanced solid tumors.
For late-stage assets, Innate is seeking partners for lacutamab in advanced T cell lymphomas, while monalizumab, partnered with AstraZeneca, is in Phase 3 PACIFIC-9 trial for non-small cell lung cancer with readouts expected by end of 2026.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco. CEO Jonathan Dickinson will present on Tuesday, January 14, 2025, from 11:15 - 11:55 am PST.
The company's executive team, including Dr Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Arvind Sood (EVP, President of US Operations), will participate in 1x1 meetings during the conference. A live video webcast of the presentation will be available on the company's website under the 'Events' tab in the Investors section.
Innate Pharma presented new data from the TELLOMAK Phase 2 study showing quality-of-life improvements in patients with cutaneous T-cell lymphoma (CTCL) treated with lacutamab. The study included 163 patients: 56 with Sézary syndrome (SS) and 107 with mycosis fungoides (MF).
Key findings for SS patients showed reduction in itch intensity from Week 5, reaching mild levels by Week 13. Skin-related symptoms improved significantly, with Skindex-29 scores decreasing from 52.7 at baseline to 14.4 by Week 45.
For MF patients, itch intensity improved from Week 5, with deeper improvement from Week 37. Skindex-29 scores showed early reductions, decreasing from 56.3 to 38.8 by Week 29.
Translational analysis revealed lacutamab's effectiveness in depleting KIR3DL2-expressing circulating tumor cells and skin cells, supporting its potential as a treatment option for SS patients.
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) have announced a partnership worth up to $7.9 million to support the development of IPH6501 in follicular lymphoma. The agreement includes a $3 million upfront investment from IFLI in Innate shares at €1.56 per share, representing 2.26% of Innate's share capital, with potential additional investments of up to $4.9 million tied to milestone achievements.
The collaboration will expand Innate's ongoing Phase 1/2 trial of IPH6501, an anti-CD20 ANKET®, to include patients with relapsed/refractory follicular lymphoma. The trial is currently investigating the safety, tolerability, and preliminary antineoplastic activity in patients with CD20-expressing Non-Hodgkin Lymphoma.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
What is Innate Pharma SA's core business?
How does the company generate revenue?
What distinguishes Innate Pharma SA’s approach to cancer treatment?
How diversified is the company’s clinical pipeline?
What role do strategic collaborations play in the company’s operations?
How does Innate Pharma SA differentiate itself from competitors?
